Rujukan Kami: (39) MOH/HQ/P/IKLAN-SH/2025

BIL	Quotation Reference	Description	Advertisement Date	Closing Date (Not Later Than 02:00PM)	Quotation Fee	Requesting Department	Focal Person
5	PPS/QTN/40/2025	1/ MEMANTINE 10MG ORAL SOLID PREPARATION PREFERABLY TABLET — QUANTITY: 110 x 60's 2/VITAMIN D3 500 IU ORAL SPRAY AS D- VITA OR ITTS EQUIVALENT (PREFERABLY PALATABLE FOR PEDIATRICS — QUANTITY: 350 x 8ML PLACE OF SUBMISSION: QUOTATION BOX (GROUND FLOOR) MINISTRY OF HEALTH COMMONWEALTH DRIVE BANDAR SERI BEGAWAN, BB 3910 NEGARA BRUNEI DARUSSALAM	25/03/2025	19/04/2025	\$5.00	JABATAN PERKHIDMATAN FARMASI KEMENTERIAN KESIHATAN.	LENNY MARLIANI BINTI HAJI RAMLI PHARMACIST DRUG PURCHASING SECTION 2393298 ext. 228

QTN REF: PPS/QTN/ 40 /2025

SUPPLY AND DELIVERY OF MEDICINES FOR THE DEPARTMENT OF PHARMACEUTICAL SERVICES

NO	DESCRIPTION OF ITEM	QUANTITY	BRAND	MANUFACTURER AND COUNTRY OF ORIGIN	PRICE AND PACK SIZE	TOTAL PRICE
1.	Memantine 10mg oral solid preparation preferably tablet	110 x 60's				
2.	Vitamin D3 500 IU oral spray as D-Vita or its equivalent [preferably palatable for pediatrics]	350 x 8ml				
First ord upon rec	Y PERIOD: er 2 months, subsequent order 1 month eipt of purchase order					

DELAY AND LIQUIDATED DAMAGES:

If the Supplier fails or is unable to deliver the Goods or any parts thereof on the Delivery Date within the time specified, the Government shall be entitled, without prejudice to claim from the Supplier by way of liquidated damages for each day of such delay, a sum of equal to one percent (1%) of the price of the Goods as stated in the relevant Purchase Order in respect of the delayed delivery, provided that the total liquidated damages shall not exceed ten percent (10%) the Purchase Order Price.

PRICE VALIDITY: The quotation shall remain valid for 6 MONTHS from the final date for the submission of the quotation, during which no supplier may withdraw his/her quotation. Where the price validity differs from that required by the Government i.e. 6 months, the LONGER VALIDITY PERIOD will be taken as the final validity period.

QTN REF: PPS/QTN/ 40 /2025

SUPPLY AND DELIVERY OF MEDICINES FOR THE DEPARTMENT OF PHARMACEUTICAL SERVICES

		TERMS AND CONDITIONS	
a.	Vendor must be registered with the Ministry of Health	Acknowledgement:	Company's Official Stamp
b.	Please complete the QUOTATION FORM including the USER REQUIREMENT FORM. Submission of incomplete forms may cause DISQUALIFICATION OF QUOTATION	I hereby certify the above quote to be	
c.	Each vendor is required to quote ONE BRAND WITH ONE PRICE ONLY for each item.	Signature:	
d.	Delivery Period: FIRST ORDER 2 MONTHS, SUBSEQUENT ORDER 1 MONTH UPON RECEIPT OF PURCHASE ORDER	Name:	
e.	PRICE VALIDITY: The quotation shall remain valid for 6 MONTHS from the final date for the submission of the quotation, during which no supplier may withdraw his/her quotation. Where the price validity differs from that required by the Government i.e. 6 months, the LONGER VALIDITY PERIOD will be taken as the final validity period.	Designation: Date:	
f.	LETTER OF UNDERTAKING (LOU): If any of the Goods to be supplied have an expiry date of less than 18 months upon delivery, vendor is required to provide letter of undertaking. The Supplier hereby		

	undertakes to: (i) replace any of the Goods with fresh, new	A STATE OF THE STA
	stock; or (ii) issue credit note equivalent to the value of the	
	expired Goods.	
f.	Please do not use correction tape or pen/fluid for amendment	

SAMPLE SUBMISSION FORM

	The Pharmacist Pharmacy Procurement Section,	Da	ate:		
	3 rd Floor, Department of Pharmaceutical Services Building Spg 433, Rimba Highway, Kg Madaras Your Ref: Ministry of Health, Negara Brunei Darussalam				
SUBM	SUBMISSION OF SAMPLES FOR QUOTATION REF: PPS / QTN / 40 / 2025				
	it sample to Pharmacy Procurement Section n f quotation advertisement.	o later than FOU	R WEEKS after <u>clo</u>	sing	
	ing to the above quotation reference, please see table below.	our feedback on	the sample submiss	sion	
NO	ITEM	SAMPLE SUBMITTED (indicate with	SAMPLE NOT SUBMITTED (indicate X with reason)		
1/	Memantine 10mg oral solid preparation preferably tablet				
2/	Vitamin D3 500 IU oral spray as D-Vita or its equivalent [preferably palatable for pediatrics]				
Thank	you.	Company	y's Official Stamp		
		Company			
Name:		Company			
	n:	Company			
Name: Positio	n:	Cumpani			
Name: Positio	on: any:				
Name: Positio Compa	en: any: FOR OFFICIAL L				
Name: Positio Compa	on: any:				

QTN REF: PPS/QTN/40/2025

No	Requirements	Enter Response Here
1	Vendor is required to submit sample in untampered original pack including package insert and Summary of Product Characteristics (in English) For Controlled drugs and Psychotropics: In the event that sample cannot be submitted, photos and/or artwork are required. See 'Presentation'.	
2	Presentation Vendor is to submit: iii. Clear colour-printed photo of the product offered with company's official stamp. Photo must show label details of the primary and secondary packaging from all sides/angles including name / brand of item, strength and form / preparation. iv. High resolution photo of the following • For tablets / capsules: • Appearance of individual tablets / capsules; • If the item is in strip pack, the back and front of the strip • For Injections: • Appearance of individual vial / ampoule / syringe	
3	Registration with Brunei Darussalam Medicines Control Authority (BDMCA) A copy of any of the following: Product Licence Certificate Letter of authorization from product licence holder, if applicable. Priority will be given to medicinal products already registered with the BDMCA.	

* *		
4	Manufacturer details	
	Please provide manufacturer details with supporting documents.	
The state of the s	If manufacturer details are not available, please provide the following:	
	iii. Hardcopy of declaration letter from the principal to inform any issues related to product safety, quality and efficacy as a result of a recall by the manufacturer, wholesaler or Department of Health iv. A copy of the principal's wholesaler license.	
5	Shelf life	
i.	Please indicate the product shelf-life, Priority will be given to product with a minimum of 24 months.	
6	Storage condition	
	The storage labelling should be in accordance with the latest guideline on registration of medicinal products in Brunei Darussalam.	
Andrew Water Community of the Community	Priority is given to products with specified storage conditions. Terms such as "ambient conditions", "room temperature" or "does not require any special storage condition" should be avoided unless stability studies are provided.	
7	Alcohol and animal content	
	Declaration of source of animal origin and/or alcohol content (if any) is to be provided.	
8	Cortificate of Analysis	
and define the second	A copy of the product's Certificate of Analysis (CoA) is to be submitted.	
L		

9	New Product	
	Where the product offered has never been supplied to the Ministry of Health, Brunei, detailed information on the product is to be submitted. The information required include, but not limited to, the following:	
	viii. Bioequivalence studies (Generic products) and / or Clinical studies ix. Stability studies x. Certificate of free sales xi. Certificate of Pharmaceutical Product (CPP) xii. A copy of the Summary of Product Characteristics xiii. Good Manufacturing Practice (GMP) certificate xiv. Batch release certificate or certificate of origin (for blood products)	
10	Price Justification	
10		
	Vendor is to submit letter of justification on price increase if the same product has been previous supplied to Ministry of Health from the same supplier / distributor.	
11	Local content & Tax Compliance Certificate	
	Vendor is to provide a copy of the latest content of the company as well as the updated tax compliance certificate, if applicable	
12	Product Registration Number in any of the *benchmark/reference countries	
	If not registered with BDMCA, priority will be given to products which are registered in any of the benchmark/reference countries.	
	*The benchmark/reference countries are Australia, Canada, Malaysia, Singapore, United Kingdom, the United States of America, France, Sweden, Japan, Switzerland, Republic of Korea & European Union.	
L		L

13 Patent Declaration

- iii. Vendors quoting generic products must provide an official declaration or confirmation from the Brunei's Intellectual Property Office verifying whether the innovator product is off-patent
- iv. Vendors quoting innovator products must provide information on the patent status and expiry in Brunei.